Alexion is accelerating the development of asfotase alfa , a first-in-class targeted enzyme replacement therapy in Phase 2 clinical trials for Hypophosphatasia (HPP). HPP is an ultra-rare, genetic and life-threatening metabolic disease with no effective treatment options. Read more
Soliris® (eculizumab) is now approved by the U.S. Food and Drug Administration (FDA) and by the
European Commission (EC) for the treatment of adult and pediatric patients with atypical hemolytic
uremic syndrome (aHUS). The effectiveness of Soliris in aHUS is based on the effects on thrombotic
microangiopathy (TMA) and renal function. Prospective clinical trials in additional patients are ongoing
to confirm the benefit of Soliris in patients with aHUS. Soliris is not indicated for the treatment of
patients with Shiga toxin E coli-related hemolytic uremic syndrome (STEC-HUS).
Click here to read the FDA approval press release, and click here to read the EC approval press release.
Click here for U.S. Prescribing Information. Click here for Important Safety information.
Members of the aHUS community discuss their experience living with aHUS and the significance of the FDA approval of Soliris as a treatment for this devastating disease.
Play Video.